Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Express Scripts Announces 2016 Third Quarter Results

Express Scripts
Posted on: 26 Oct 16

ST. LOUIS, Oct. 25, 2016 /PRNewswire/ -- Express Scripts Holding Company (Nasdaq: ESRX) announced 2016 third quarter net income of $722.9 million, or $1.15 per diluted share.  2016 third quarter adjusted earnings per diluted share, as detailed in Table 4, was $1.74.1

"The healthcare industry demands that we stay ahead of future trends and deliver solutions to emerging issues facing today's market," said Tim Wentworth, CEO and President.  "Doing so deepens the trusted relationships we have built with our clients, resulting in another strong year in terms of client retention and new sales."

Third Quarter 2016 Review  

The following compares third quarter 2016 and 2015 operating results:

Adjusted claims of 312.2 million, down 5%, largely due to faster roll-off of the Coventry business – See Table 1

Net income of $722.9 million, up 9%

Diluted earnings per share of $1.15, up 19%

EBITDA of $1,948.1 million, up 8% from 2015 adjusted EBITDA – See Table 32

EBITDA per adjusted claim of $6.24, up 13% from 2015 adjusted EBITDA per adjusted claim – See Table 32 

Adjusted net income of $1,091.6 million, up 10% – See Tables 5 and 5A

Adjusted diluted earnings per share of $1.74, up 20% - See Table 4

Net cash flow provided by operating activities of $1,480.4 million, up 87%

In July 2016, the Company issued senior notes consisting of: $1,000.0 million aggregate principal amount of 3.000% senior notes due July 2023, $1,500.0 million aggregate principal amount of 3.400% senior notes due March 2027 and $1,500.0 million aggregate principal amount of 4.800% senior notes due July 2046.  The Company used the net proceeds to repay a portion of its 2015 two-year term loan, to complete a tender offer for and follow-on redemption of its 2.650% senior notes due February 2017, to complete a tender offer for a portion of each of the 7.125% senior notes due March 2018 issued by Medco Health Solutions, Inc., the 7.250% senior notes due June 2019 issued by Express Scripts, Inc. and the Company's 6.125% senior notes due November 2041 and for other general corporate purposes.  Total cash payments related to the above, excluding accrued interest, were $3,919.6 million, which included approximately $136.0 million of repayment costs. 

In August 2016, the Company settled the accelerated share repurchase ("ASR") program announced in February 2016, and received 6.2 million additional shares, resulting in a total of 38.3 million shares repurchased under the program.  Including the 6.2 million shares received under the 2016 ASR program, the Company repurchased a total of 14.1 million shares under our share repurchase program for $1,132.5 million during the quarter.

2016 Guidance

The Company narrowed its 2016 earnings per diluted share guidance from a range of $4.45 to $4.55 to a range of $4.47 to $4.53, which maintains the mid-point of $4.50 and represents growth of 26% to 27% over 2015.  The Company narrowed its 2016 adjusted earnings per diluted share guidance from a range of $6.33 to $6.43 to a range of $6.36 to $6.42, which raises the mid-point to $6.39 and represents growth of 15% to 16% over 2015.  Additional details on this guidance can be found in Table 6 including items excluded from the adjusted earnings per diluted share guidance range.

The Company expects total adjusted claims for the fourth quarter of 2016 to be in the range of 314 million to 329 million.  Diluted earnings per share for the fourth quarter of 2016 is expected to be in the range of $1.38 to $1.44, which represents growth of 22% to 27% over the fourth quarter of 2015.  Adjusted diluted earnings per share for the fourth quarter of 2016 is estimated to be in the range of $1.84 to $1.90, which represents growth of 18% to 22% over the fourth quarter of 2015. Additional details on this guidance can be found in Table 6 including items excluded from the adjusted earnings per diluted share guidance range.

2016 Business Outlook

The Company is increasing its expected 2017 retention rate for the 2016 selling season to a range of 97% - 98% from a range of 96% - 98%, excluding the impact of the remaining Coventry business rolling off in 2017, representing approximately 1% of claims.  

About Express Scripts

Express Scripts puts medicine within reach of tens of millions of people by aligning with plan sponsors, taking bold action and delivering patient-centered care to make better health more affordable and accessible.

Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery pharmacy care, specialty pharmacy care, specialty benefit management, benefit-design consultation, drug utilization review, formulary management, and medical and drug data analysis services.  Express Scripts also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.

For more information, visit Lab.Express-Scripts.com or follow @ExpressScripts on Twitter.

For more information:
www.prnewswire.com/news-releases/express-scripts-announces-2016-third-quarter-results-300351012.html

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 26/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.